Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DR10624 in moderate hypertriglyceridemia with diabetic kidney disease
CTR20262589Phase 2Active
- Sponsor
- Zhejiang Daer Biotechnology
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertriglyceridemia, diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing DR10624 with Placebo (2 arms). Primary endpoint: Percent change from baseline in fasting triglycerides. Started Jul 2026; status: active.
02
Drugs
DR10624
03
Conditions
hypertriglyceridemiadiabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20262589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262589.